Eli Lilly and Company is discontinuing development of the basal insulin peglispro (BIL), a candidate treatment for Type 1 and Type 2 diabetes, following increases in a key liver enzyme in patients enrolled in Phase 3 trials of the drug. ---Subscribe to MedNous to access this article--- Clinical Research Company News
